HCA Healthcare has upgraded its guidance, anticipating an additional $2 billion in revenue and nearly $1 billion in Adjusted EBITDA, driven by easing labor shortages and inflation. Despite risks from payer negotiations and potential cost growth, the company is positioned for margin expansion and solid revenue growth, prompting a rating increase from hold to buy with a price target of $447, reflecting an 8% upside. The upcoming Q3 earnings are expected to show strong performance, with a focus on margin and cost management.